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Abstract 
Background: High‑frequency oscillatory ventilation (HFOV) does not improve the prognosis of ARDS patients 
despite an improvement in oxygenation. This paradox may partly be explained by HFOV hemodynamic side‑effects 
on right ventricular function. Our goal was to study the link between HFOV and hemodynamic effects and to test if 
the pre‑HFOV right over left ventricular end‑diastolic area (RVEDA/LVEDA) ratio, as a simple parameter of afterload‑
related RV dysfunction, could be used to predict HFOV hemodynamic intolerance in patients with severe ARDS.
Methods: Twenty‑four patients were studied just before and within 3 h of HFOV using transthoracic echocardiogra‑
phy and transpulmonary thermodilution.
Results: Before HFOV, the mean PaO2/FiO2 ratio was 89 ± 23. The number of patients with a RVEDA/LVEDA ratio >0.6 
significantly increased after HFOV [11 (46 %) vs. 17 (71 %)]. Although HFOV did not significantly decrease the arterial 
pressure (systolic, diastolic, mean and pulse pressure), it significantly decreased the cardiac index (CI) by 13 ± 18 % 
and significantly increased the RVEDA/LVEDA ratio by 14 ± 11 %. A significant correlation was observed between 
pre‑HFOV RVEDA/LVEDA ratio and CI diminution after HFOV (r = 0.78; p < 0.0001). A RVEDA/LVEDA ratio superior to 
0.6 resulted in a CI decrease >15 % during HFOV with a sensitivity of 80 % (95 % confidence interval 44–98 %) and a 
specificity of 79 % (confidence interval 49–95 %).
Conclusion: The RVEDA/LVEDA ratio measured just before HFOV predicts the hemodynamic intolerance of this tech‑
nique in patients with severe ARDS. A high ratio under CMV raises questions about the use of HFOV in such patients.
Trial registration: ClinicalTrials.gov: NCT01167621
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Background
In severe acute respiratory distress syndrome (ARDS), 
alternative therapies are indicated [1] when protec-
tive conventional mechanical ventilation (CMV) fails 
to maintain efficient gas exchange. High-frequency 
oscillatory ventilation (HFOV) is a non-CMV technique 
that could improve alveolar recruitment and achieve 
protective ventilation with the most severe cases of 
ARDS using very low tidal volume (VT) and relatively 
high mean airway pressure (mPaw) as a surrogate for 
positive end-expiratory pressure (PEEP). Previous stud-
ies have clearly shown an improvement in oxygenation 
with HFOV [2] and even suggest a reduction in mortality 
[3, 4] although the level of improvement in oxygenation 
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is unpredictable and HFOV can indeed worsen oxygena-
tion in some patients [5]. Alveolar recruitment—and 
thus improvement in gas exchange—seems to depend on 
the level of mPaw [6, 7] and a high mPaw (around 30 cm 
H2O) for a period of several days seems to give the best 
results [6]. Unfortunately, two large, multicenter, ran-
domized controlled trials recently raised doubts about 
the safety of HFOV: the first [8] showed no significant 
effect on 30-day mortality and, troublingly, the sec-
ond [9] was prematurely discontinued following a non-
significant but constant increase in mortality at each 
interim analysis. This paradox—an improvement in oxy-
genation in most cases on the one hand but no mortal-
ity reduction on the other—may partly be explained by 
the hemodynamic side-effects of HFOV. Indeed, a ret-
rospective study [5] involving 190 patients treated by 
HFOV reported a high rate of hemodynamic complica-
tions (27  %). A study involving only nine patients with 
high mPaw HFOV showed a decrease in cardiac index 
(CI), probably due to airway pressure-related preload 
reduction [10]. Finally, a study involving 16 patients 
demonstrated that HFOV could worsen right ventricular 
function [11]. Therefore, our goal was to monitor hemo-
dynamic effects during the first 3  h with high mPaw 
HFOV using transthoracic echocardiography (TTE) and 
transpulmonary thermodilution (TPTD) and to assess if 
afterload-related RV dysfunction measured just before 
HFOV like the right over left ventricular end-diastolic 




This observational prospective study was approved by the 
ethics committee of Bordeaux University Hospital (Com-
ité de Protection des Personnes Sud-Ouest et Outre-Mer 
III, no. 2010-A00338-31).Written informed consent was 
obtained from each patient’s next of kin.
In our 18-bed intensive care unit (ICU), VMC therapy 
for ARDS was set according to a standardized proto-
col for maximal alveolar recruitment: protective CMV 
consisted of a volume-controlled mode with a VT of 
6  mL  kg−1 of predicted body weight (PBW), maximal 
PEEP without exceeding a plateau airway pressure of 30 
cm H2O [12], controlled sedation for a Ramsay Score >5 
[13] followed by continuous infusion of cis-atracurium 
[14] and systematic use of a heated humidifier and a 
closed endotracheal suction catheter [15]. All patients 
were hemodynamically optimized according to TPTD 
monitoring PiCCO2 (Pulsion Medical Systems, Munich, 
Germany) and/or TTE monitoring [16, 17].
In our unit, refractory ARDS was defined as follows:
  • Life-threatening hypoxemia (PaO2/FiO2 <70 mmHg) 
at any time during the first 12 h of CMV for maximal 
alveolar recruitment
  • When one of more of the following criteria are 
met after 12  h of CMV: arterial blood oxygen 
saturation  <90  % with fraction of inspired oxy-
gen (FiO2)  =  1; PaO2/FiO2 ratio  <120; hypercap-
nia >55 mmHg or pH <7.20 despite a respiratory rate 
of 35  min−1, plateau airway pressure  >30 cm H2O 
with a tidal volume of 6 mL kg−1 of PBW and a 5 cm 
H2O minimal PEEP.
When a patient exhibited these criteria for refractory 
ARDS, rescue therapies were considered (i.e., HFOV, 
prone positioning [18] or extra-corporeal membrane 
oxygenation (ECMO) [19]). Patients undergoing HFOV 
were enrolled in the study from May 2010 to November 
2012 if the following criteria were met:
  • Refractory ARDS
  • HFOV used as an alternative therapy to CMV
  • A TPTD device used for hemodynamic monitoring
  • Hemodynamic stability during the 10  min prior to 
HFOV (mean arterial pressure stable and between 
65 and 85 mmHg, no CI variation of more than 10 % 
given by the PiCCO2 beat-to-beat pulse contour 
analysis, no change in norepinephrine dose).
Exclusion criteria were:
  • Age <18 years
  • Moribund status
  • Contraindications to HFOV (head injury, pneumo-
thorax or persistent air leak despite chest tube inser-
tion)
  • Hemodynamic instability before HFOV
  • Poor echogenicity preventing appropriate echocar-
diographic assessment by TTE.
HFOV
Initial settings and parameter adjustment
At inclusion, HFOV (3100B SensorMedics ventilator, 
Yorba Linda, CA, USA) was initially set as follows: FiO2 
1; frequency 6  Hz; bias flow 40 L  min−1; mPaw 10 cm 
H2O above the CMV mPAw up to a maximum of 30 cm 
H2O and pressure amplitude of oscillation 80 %. During 
the 3-h protocol, mPaw and bias flow were not modified; 
other parameters were adjusted as follows:
  • FiO2 adjusted to obtain a PaO2 of 60–85 mmHg
  • Frequency and pressure amplitude of oscillation 
adjusted to obtain a pH >7.25 and a PCO2 <55 mmHg
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HFOV failure criteria
HFOV was defined as a failure if at least one of the fol-
lowing occurred:
  • Oxygen saturation fell below 90 % despite a FiO2 1
  • PaO2/FiO2 ratio <70
  • Hypercapnia  >55  mmHg and/or pH  <7.20 despite a 
frequency of 3.5 Hz and pressure amplitude of oscil-
lation of 100 %
  • Occurrence of a new pneumothorax.
We defined HFOV-associated hemodynamic failure as 
major hemodynamic instability linked to HFOV: signifi-
cant arterial hypotension (systolic arterial pressure under 
90 mmHg or a decrease >30 % of initial systolic pressure) 
and/or CI decrease >30 %.
When HFOV failure was ascertained, CMV was 
removed leading to the termination of the study and an 
alternative method of oxygenation (prone positioning 
or ECMO) was initiated. If systolic arterial pressure was 
under 90 mmHg, the norepinephrine dose was increased 
during the HFOV–CMV transfer process.
Hemodynamic measurements
The study began at patient inclusion, i.e., under CMV 
during a 10-min period before initiation of HFOV, and 
ended 3 h later. The different stages of the study were:
  • Just before initiation of HFOV (CMVpre)
  • Connection to HFOV (HFOV connection)
  • After 1 h of HFOV (H1 HFOV)
  • After 3 h of HFOV (H3 HFOV)
In each sequence, heart rate, arterial pressure, catecho-
lamine and sedation dose rates and TTE and TPTD data 
were recorded.
TTE measurements
TTE were performed by a single experienced echocardi-
ographer. Images were acquired using an EnVisor Philips 
HD 11XE (Philips Medical System, Andover, MA, USA) 
scanner and a 3 MHz transducer. Two-dimensional (2D) 
imaging examinations were performed in the standard 
apical four- and two-chamber views (4C- and 2C-views). 
Tissue harmonic imaging was used to enhance 2D image 
quality. Left ventricular ejection fraction (LVEF) was 
measured either by the biplane or monoplane Simpson 
method [20]. The velocity–time integral in the left ven-
tricular outflow tract (LVOT VTI) was measured using 
pulsed wave Doppler in the apical five-chamber view. 
LVEDA and RVEDA were measured in the 4C-view. 
Echocardiographic patterns of acute cor pulmonale 
(ACP) associating RVEDA/LVEDA ratio >0.6 and systolic 
septal dyskinesia on a short-axis view were looked for 
[21]. LV filling parameters were assessed in the 4C-view 
and using pulsed wave and tissue Doppler imaging in 
accordance with the current standards [22, 23]. All TTE 
studies were recorded over three consecutive cardiac 
cycles independently of the respiratory cycle and aver-
aged. In patients with non-sinus rhythm, measurements 
were collected over 5–7 heartbeats.
TPTD measurements
Injection of 15  mL of cold saline through the central 
venous line was performed in triplicate, and the values of 
the different TDTP parameters [CI, stroke volume index 
(SVI), global end-diastolic index (GEDI) and cardiac 
function index (CFI)] were averaged [24].
Respiratory measurements
For each sequence, ventilator settings, respiratory sys-
tem mechanical parameters, arterial blood gas analysis, 
extravascular lung water index (ELWI) and pulmonary 
vascular permeability water index (PVPI) obtained by 
TPTD were collected [25, 26].
Statistical analysis
Qualitative variables were described in frequencies and 
proportions. Quantitative variables were described in 
means and standard deviations. Evolution of hemo-
dynamic and respiratory levels during the study was 
assessed using a linear mixed model adjusted for time. 
A first-order autoregressive variance–covariance matrix 
was specified, to account for the correlated repeated time 
data. All multiple comparisons were performed using 
the Scheffe adjustment. The receiver operating charac-
teristics curve was constructed to assess the ability of an 
RVEDA/LVEDA ratio at inclusion to predict a decrease 
in CI >15 % with HFOV. Spearman rank correlation anal-
ysis was used to assess the relationship between RVEDA/
LVEDA ratio at inclusion and changes in CI on HFOV. 
Statistical analysis was performed using the SAS 9.2 soft-
ware (SAS Institute, Cary, NC, USA). All hypotheses 
were tested at the 2-tailed 0.05 significance level.
Results
Twenty-four patients (7 women and 17 men) were 
included in the study. None of them had a history of 
chronic respiratory failure. The mean time between ICU-
CMV and HFOV was 9  ±  4  h. Twenty-three patients 
were still under HFOV at H1 (one patient was withdrawn 
for hemodynamic failure), and 19 at H3 (two patients 
were withdrawn for respiratory failure and two more for 
hemodynamic failure).
On admission, the Simplified Acute Physiology Score II 
(SAPS II) and the Sequential Organ Failure Assessment 
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(SOFA) were, respectively, 60 ± 17 and 12 ± 3. Mortal-
ity at D28 was 46  %. Causes of ARDS were pulmonary 
for 75 % of patients (n = 18) (thirteen cases of infectious 
pneumonia, four aspiration pneumonia and one drown-
ing accident), and extra-pulmonary for 25  % of patients 
(n  =  6). At baseline, 21 patients (82  %) were receiving 
norepinephrine and three dobutamine. The respiratory 
variables during CMV at baseline are summarized in 
Table 1.
Hemodynamic parameters
Rate and cause of hemodynamic failure
Hemodynamic failure was reported in three patients 
(12  %), occurring within the first 90  min after HFOV. 
These three patients had an ACP echocardiographic pat-
tern not only during CMV but also after HFOV.
Hemodynamic effects of HFOV
As shown in Table 2, although HFOV did not significantly 
decrease arterial pressure (systolic, diastolic, mean and 
pulse pressure), it significantly decreased CI by 13 ± 11 % 
from 3.7 ± 1.1 L min−1 m−2 at baseline and LVOT VTI 
by 13 ± 12 % from 17 ± 5 cm at baseline. SVI, GEDI, CFI, 
LVEF and E/A ratio also significantly decreased, whereas 
the RVEDA/LVEDA ratio increased by 14 ± 11 %, from 
0.61 ± 0.15 at baseline. The number of patients with an 
RVEDA/LVEDA ratio >0.6 and with an ACP echocardio-
graphic pattern significantly increased during HFOV [11 
(46 %) vs. 17 (71 %) and 5 (21 %) vs. 11 (46 %), respec-
tively]. For each patient, RVEDA/LVEDA ratio on inclu-
sion was compared with the percentage change in TDTP 
CI between inclusion and HFOV. When considering 
these 24 pairs of measurements, a significant inverse cor-
relation was observed (r  =  −0.78; p  <  0.0001) (Fig.  1). 
An RVEDA/LVEDA ratio superior to 0.6 predicted a 
decrease in CI >15 % during HFOV with a sensitivity of 
80 % (95 % confidence interval 44–98 %) and a specificity 
of 79 % (confidence interval 49–95 %) (Fig. 2).
Hemodynamic changes during the first 3 h of HFOV
There was no hemodynamic change during the first 3 h 
with the exception of E-wave, E/A ratio, RVEDA/LVEDA 
ratio and numbers of ACP echocardiographic patterns 
(Table 2).
Therapeutic interventions by the attending physicians
During the 3-h study, no volume expansion was admin-
istered to patients and there was no significant change 
in doses of catecholamines, sedative drugs or cisatracu-
rium. Therapeutic interventions were carried out only on 
the three patients with HFOV-associated hemodynamic 
failure.
Respiratory parameters
Respiratory parameter changes are summarized in 
Table 3. The comparison of PaO2/FiO2 ratios revealed a 
significant increase of 90 % or more between the HFOV 
sequences and CMVpre sequence.
At H1 HFOV, the PaO2/FiO2 ratio increased from the 
baseline value by more than 100  % for 39  % of patients 
and by more than 30 % for 61 % of patients.
At H3 HFOV, the PaO2/FiO2 ratio increased from the 
baseline value by more than 100  % for 47  % of patients 
and by more than 30 % for 74 % of patients.
During the study, there was no significant difference 
between the mean PaO2/FiO2 ratios of the 18 patients 
with pulmonary ARDS and the 6 patients with extra-
pulmonary ARDS (91  ±  22 vs. 83  ±  27 at inclusion, 
180 ± 104 vs. 147 ± 119 at H1 and 186 ± 81 vs. 158 ± 131 
at H3, respectively).
Discussion
To our knowledge, this study is the largest that focuses 
specifically on hemodynamic changes during HFOV. It 
confirms the significant CI decrease linked to HFOV. It 
also suggests that the initial pre-HFOV RVEDA/LVEDA 
ratio can predict the hemodynamic intolerance induced 
by HFOV.
Table 1 Respiratory variables at baseline
Results are given as mean ± SD
ABG arterial blood gas, TPTD transpulmonary thermodilution, VT tidal-volume, 
PBW predicted body weight, PEEP positive end-expiratory pressure, FiO2 
fraction of inspired oxygen, mPaw mean airway pressure, P/F ratio of arterial 
oxygen concentration to the fraction of inspired oxygen, PaCO2 partial pressure 
of arterial carbon dioxide, PaO2 partial pressure of arterial oxygen, ELWI 
extravascular lung water index, PVPI pulmonary vascular permeability index
Ventilator settings
 VT (mL kg−1 PBW) 5.8 ± 0.6
 Respiratory rate (cycles min−1) 29 ± 3
 PEEP (cm H2O) 11 ± 3
 FiO2 (%) 97 ± 9
Respiratory‑system mechanics
 Plateau airway pressure (cm H2O) 29 ± 2
 mPaw (cm H2O) 19 ± 3
 Respiratory system compliance (mL cm H2O
−1) 22 ± 9
Results of ABG measurements
 pH 7.24 ± 0.14
 P/F ratio 89 ± 23
 PaO2 (mmHg) 86 ± 22
 PaCO2 (mmHg) 53 ± 15
 Bicarbonate (mmol L−1) 24 ± 5
 Base excess (mmol L−1) −6 ± 6
TDTP respiratory parameters
 ELWI (mL kg−1 PBW) 19 ± 7
 PVPI 5.1 ± 1.7
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Although right heart dysfunction is a commonly 
reported side-effect of ARDS protective ventilation 
[27], only two prospective studies have specifically 
focused on the hemodynamic effects of HFOV, with 
both transesophageal echocardiography (TEE) and right 
heart catheterization monitoring. David et  al. reported 
a clinically significant decrease in CI and SVI thought 
to be related to a preload decrease [10]. Guervilly et  al. 
described a right ventricular dysfunction in HFOV pro-
portional to the mPaw setting level [11].
Our results are in accordance with those two studies, 
since HFOV led to a 13 % decrease in CI and to a 14 % 
increase of RVEDA/LVEDA. The proportion of patients 
with a ratio above 0.6 (46  %) is comparable with that 
reported by Guervilly et al. (56 %) [11].
The initial pre-HFOV RVEDA/LVEDA ratio is a good 
predictive factor of HFOV hemodynamic intolerance, 
as shown by the strong correlation of 78  % (r2  =  0.61) 
Table 2 Evolution of the hemodynamic characteristics during the study
Results are given as mean ± SD
CMV conventional mechanical ventilation, HFOV high frequency oscillation ventilation, TPTD transpulmonary thermodilution, SVI stroke volume index, GEDI global 
end diastolic index, CFI cardiac function index, LVEF left ventricular ejection fraction, TTE transthoracic echocardiography, LVEDA left ventricular end diastolic area, 
RVEDA right ventricular end diastolic area, LVOT VTI velocity–time integral in the left ventricular outflow tract, DTE E-wave deceleration time
a p < 0.05 for all data as compared to CMVpre
b p < 0.05 for all data as compared to HFOV Connection
c p < 0.05 for all data as compared to H1 HFOV
d p < 0.05 for all data as compared to H3 HFOV
CMVpre HFOV connection H1 HFOV H3 HFOV
Concerned patients number 24 24 23 19
Heart rate (beats/min) 102 ± 22 102 ± 23 102 ± 23 102 ± 24
Systolic arterial pressure (mmHg) 120 ± 18 119 ± 23 119 ± 19 116 ± 17
Diastolic arterial pressure (mmHg) 62 ± 11 63 ± 12 65 ± 11 62 ± 11
Mean arterial pressure (mmHg) 81 ± 11 81 ± 13 80 ± 14 80 ± 12
Pulse pressure (mmHg) 57 ± 13 56 ± 17 54 ± 17 54 ± 13
Cardiac index (L min−1 m−2) (TPTD) 3.7 ± 1.1b,c,d 3.3 ± 1.3a 3.3 ± 1.2a 3.1 ± 1.1a
SVI (mL min−1 m−2) (TPTD) 36 ± 11b,c,d 33 ± 14a 33 ± 14a 32 ± 14a
GEDI (mL min−1 m−2) (TPTD) 680 ± 140b,c,d 634 ± 134a 646 ± 126a 625 ± 112a
CFI (min−1) (TPTD) 5.5 ± 1.8b,c,d 5.2 ± 1.9a 5.0 ± 1.8a 5.0 ± 1.5a
LVEF (%) (TTE) 53 ± 16b,c,d 50 ± 17a 49 ± 15a 49 ± 13a
RVEDA/LVEDA ratio (TTE) 0.61 ± 0.15b,c,d 0.70 ± 0.18a 0.72 ± 0.18a 0.67 ± 0.14a
RVEDA/LVEDA ratio >0.6 [n (%)] 11 (46)b,c 17 (71)a,d 17 (74)a,d 10 (53)b,c
ACP echocardiographic pattern [n (%)] 5 (21)b,c 11 (46)a,d 10 (43)a,d 6 (32)b,c
LVOT VTI (cm) (TTE) 17 ± 5b,c,d 14 ± 5a 14 ± 5a 14 ± 5a
E‑wave (cm s−1) (TTE) 90 ± 23c 86 ± 20c 80 ± 21a,b,d 91 ± 22c
A‑wave (cm s−1) (TTE) 57 ± 16 58 ± 12 54 ± 12 57 ± 15
E′ (cm s−1) (TTE) 14 ± 5 14 ± 5 14 ± 4 15 ± 5
DTE (ms) (TTE) 207 ± 51 204 ± 44 213 ± 38 205 ± 46
E/A (TTE) 1.8 ± 0.5b,c 1.6 ± 0.6a 1.6 ± 0.5a 1.8 ± 0.7b,c
E/E′ (TTE) 8.3 ± 2.9 8.4 ± 2.9 7.4 ± 3.6 8.0 ± 3.0
Norepinephrine (μg kg−1 min−1) 0.59 ± 0.78 0.59 ± 0.78 0.58 ± 0.78 0.53 ± 0.69
Fig. 1 Inverse correlation between the right over left ventricular end‑
diastolic area at inclusion and changes in cardiac index during HFOV. 
Line linear regression line
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between the pre-HFOV ratio and the CI decrease 
induced by HFOV and the sensitivity (80  %) and speci-
ficity (79  %) values found to predict a decrease in 15  % 
CI by a CMV pre-HFOV RVEDA/LVEDA superior to 0.6. 
Such results underline the value of performing an echo-
cardiography before HFOV to assess the RVEDA/LVEDA 
ratio and the risk of right ventricular dysfunction. In our 
study, the exact pathophysiology of right ventricular dys-
function cannot be explained given the lack of pulmo-
nary vascular resistance monitoring.
Although our definition of refractory ARDS is nei-
ther published nor consensual, these patients had severe 
ARDS after 12 h of CMV maximum alveolar recruitment 
with a mean PaO2/FiO2 ratio of 89 ± 23. This new prac-
tice of delaying ARDS severity ranking is of key impor-
tance as it precludes inclusion of initially severe ARDS 
patients showing rapid improvement with CMV once 
set to maximal alveolar recruitment. Although our study 
was designed before the new Berlin definition for ARDS 
[28], its HFOV utilization is very close to that proposed 
by experts [29]. The early and very brief use of HFOV 
for 3 h for severe ARDS patients improved oxygenation 
in 66 % of cases. These data are consistent with a recent 
retrospective study [30] in which the early response to 
HFOV (an improvement of more than 38 % in the PaO2/
FiO2 ratio) was identified as a predictor for survival at 
day 30. Therefore, HFOV could be used in the future as 
a recruitment technique, possibly applied sequentially 
as for prone positioning. This new approach is currently 
being studied in our ICU.
It must be said that the two recently published large 
randomized controlled trials, OSCILLATE [9] and 
Fig. 2 Receiver operating characteristic curve showing the ability of 
the right over left ventricular end‑diastolic area at inclusion to detect 
a cardiac index decrease ≥15 % during HFOV. RVEDA right ventricular 
end diastolic area, LVEDA left ventricular end diastolic area
Table 3 Evolution of the respiratory and gazometric parameters during the study
Results are given as mean ± SD
CMV conventional mechanical ventilation, HFOV high frequency oscillation ventilation, mPaw mean airway pressure, FiO2 fraction of inspired oxygen, P/F ratio of 
arterial oxygen concentration to the fraction of inspired oxygen, OI oxygenation index calculated as (mean airway pressure × FiO2)/PaO2, ELWI extravascular lung 
water index, PBW predicted body weight, PVPI pulmonary vascular permeability index
a p < 0.05 for all data as compared to CMVpre
b p < 0.05 for all data as compared to HFOV connection
c p < 0.05 for all data as compared to H1 HFOV
d p < 0.05 for all data as compared to H3 HFOV
CMVpre HFOV connection H1 HFOV H3 HFOV
Concerned patients number 24 24 23 19
mPaw (cm H2O) 19 ± 3b,c,d 29 ± 1a 28 ± 1a 29 ± 1a
Frequency (Hz) NA 6.0 ± 0.0d 6.0 ± 0.0d 5.2 ± 1.3b,c
Amplitude (cm H2O) NA 88 ± 13 86 ± 12 85 ± 12
Pressure amplitude of oscillation (%) NA 80 ± 0 79 ± 4 79 ± 5
pH 7.24 ± 0.14d NA 7.25 ± 0.16 7.30 ± 0.17a
PaCO2 (mmHg) 53 ± 15d NA 49 ± 19a 47 ± 15a
Bicarbonate (mmol L−1) 24 ± 5 NA 23 ± 6 24 ± 4
Base excess (mmol L−1) −6 ± 6d NA −6 ± 7d −4 ± 5a,c
P/F ratio 89 ± 23c,d NA 171 ± 106a 177 ± 96a
OI 26 ± 8d NA 26 ± 17d 23 ± 15a,c
ELWI (mL/kg PBW) 19 ± 7 19 ± 7 19 ± 7 17 ± 6
PVPI 5.1 ± 1.7 5.2 ± 1.8 5.1 ± 1.5 5.1 ± 1.7
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OSCAR [8] comparing HFOV with a conventional lung-
protective ventilation, casted doubt over HFOV, sug-
gesting no benefit or even a worse outcome on adults 
with  HFOV  with early moderate to severe ARDS. But 
despite strong compliance with current recommenda-
tions of protective ventilation from the ARDS network 
[31] and prompt initiation of HFOV in these two studies, 
randomization was performed on patients with moder-
ate to severe ARDS (PaO2/FiO2 <200), not severe ARDS 
patients only. Furthermore, the randomization was con-
ducted regardless of early clinical evolution under CMV 
and the use of muscle relaxants was practitioner depend-
ant. In the OSCILLATE study [9], the use of very high 
mPaw, without ruling out risk of potential hemodynamic 
failure, may have led to an excess mortality in the HFOV 
arm of this study. These two studies have given rise to 
three recent meta-analyses including 6 RCTs for 1608 
patients [32], 5 RCTs for 1580 patients [33] and 7 RCTs 
for 1759 patients [34] without confirming better survival 
or higher mortality with HFOV.
Our study has several limitations. Its observational 
design with non-consecutive patients could engender 
a selection bias. The study population is small given 
the monocentric screening and the stringent inclu-
sion criteria. Even if only a single experienced operator 
performed TTE, a post hoc analysis by an independent 
expert could have confirmed the hemodynamic data 
obtained by blinded practitioners. Similarly, data were 
obtained by TTE and not TEE, which, in the context of 
HFOV, could cast doubts on the accuracy of the results. 
Yet, TTE-obtained data are consistent with those found 
by TPTD (e.g., LVOT VTI and TPTD CI both decreased 
by 13  % on HFOV) and comparable to those obtained 
by Guervilly et  al. with TEE [11]. Another limitation of 
the study is the lack of assessment of a potential preload 
decrease during HFOV. The only way to test this would 
have been a comparison of the passive leg raising results 
at inclusion and during HFOV since pulse pressure vari-
ation, stroke volume variation, vena cava variations and 
tele-expiratory occlusion test cannot be used with HFOV. 
Unfortunately, this test is very difficult to implement 
with HFOV and would have slowed and complicated 
the protocol. Lastly, it is unfortunate that we could not 
compare TTE data with those obtained by a pulmonary 
artery catheter (PAC) to better assess right ventricular 
function. However, our study was strictly observational 
and we routinely use TPTD and not PAC for monitor-
ing patients with severe ARDS. This enables us to better 
assess the risk/benefit ratio of volume expansion based 
on ELWI and PVPI rather than on pulmonary capillary 
pressure [35, 36]. In this context, we considered it unethi-
cal to insert a PAC in addition to a TPTD device only for 
the purpose of the study.
Conclusion
This study suggests that the RVEDA/LVEDA ratio meas-
ured just before HFOV is a predictor of the hemody-
namic intolerance of this technique in patients with 
severe ARDS. A high value of this ratio observed under 
CMV should question the use of HFOV in such patients.
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